# AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
Author: Pal sinha, Barnali
Author URL: https://startupobserver.com/author/pal-sinha-barnali/
Published: 2023-06-09
Category: Headlines
Category URL: https://startupobserver.com/category/headlines/
Meta Title: AstraZeneca partners with Quell for $2 billion cell therapy deal
Meta Description: AstraZeneca partners with Quell Therapeutics in $2 billion deal to develop potentially curative cell therapies for autoimmune diseases like type 1 diabetes and inflammatory bowel disease.
URL: https://startupobserver.com/astrazeneca-signs-2-billion-agreement-with-quell-to-develop-cell-therapies/

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qsrmdo0032wirgrt84jr62/images/2023-06-09t080503z2lynxmpej58078rtroptp4astrazeneca-quell-therapeutics-autoimmune-1737044237683-compressed.jpg)

(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell [therapies](https://startupobserver.com/gsk-bets-2-billion-on-bellus-cough-drug-to-soothe-pipeline-fears/) that could cure autoimmune diseases.

The [agreement](https://startupobserver.com/nokia-signs-5g-patent-deal-with-chinas-vivo/) includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from [AstraZeneca,](https://startupobserver.com/astrazeneca-planning-china-business-spin-off-ft/) and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---